Chart-Typ:
Zeitraum:
| AstraZeneca PLC: AstraZeneca announces equity investment in Summit Therapeutics Inc. | 29 September 2026
AstraZeneca announces strategic equity investment and clinical
collaboration with Summit Therapeutics to advance
leading ADC combination strategy in cancer
Clinical collaboration... ► Artikel lesen |
| Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen |
| Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | Anzeige / Werbung
Mehr als 30 Milliarden US-Dollar Umsatz mit einem einzigen Medikament: Keytruda von Merck & Co. (ISIN: US58933Y1055) gehört zu den wertvollsten Arzneimitteln der Welt. 2025
erzielten... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 | ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for... ► Artikel lesen |
| Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen |
| Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2026 Financial Results | SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter... ► Artikel lesen |
| Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.